Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data
Guardado en:
Autores principales: | Mustafa Kürşat Tigen, Mehmet Hasan Özdil, Altuğ Çinçin, Emre Gürel, Murat Sünbül, Anıl Şahin, Tuba Güçtekin, Zekeriya Doğan, Nurten Sayar, Beste Özben |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KARE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c8642e439ea24e6da95ee587a831158f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Predictive value of the age, creatinine and ejection fraction score in patients undergoing primary percutaneous coronary intervention with bail-out tirofiban therapy
por: Altuğ Ösken, et al.
Publicado: (2021) -
Management of acute perioperative myocardial infarction: a case report of concomitant acute myocardial infarction and tumor bleeding in the transverse colon
por: Li YF, et al.
Publicado: (2016) -
Safety and Efficacy of Tirofiban During Mechanical Thrombectomy for Stroke Patients with Preceding Intravenous Thrombolysis
por: Huo X, et al.
Publicado: (2020) -
Efficacy and safety of tirofiban injection with intracranial stenting in early reocclusion due to intracranial atherosclerosis
por: Yun Ho Noh, et al.
Publicado: (2022) -
Influence of Tirofiban maintenance duration on patients with acute myocardial infarction treated by percutaneous coronary intervention
por: Zhen-Guo Ji, et al.
Publicado: (2015)